Glass in AuroMedics injectables vial prompts US recall

By Flora Southey contact

- Last updated on GMT

GettyImages/NikiLitov
GettyImages/NikiLitov

Related tags: Pharmaceutical drug

A piece of glass found in a vial of generic injectable product Pantoprazole Sodium has prompted AuroMedics Pharma to issue a nationwide voluntary recall.

The complaint concerns Pantaprazole Sodium for injection 40gm per vial lot CPO170035 – first shipped to US hospitals and/or wholesalers on August 7, 2017 – used for the short term treatment of gastroesophageal reflux disease.

The treatment also has a history of erosive esophagitis and pathological hypersecretion including zollinger-ellison syndrome.

The US Food and Drug Administration (FDA) said the administration of a glass particulate in an intravenous drug could result in local irritation or swelling.

“More serious potential outcomes would include blockage and clotting in blood vessels, which may be life-threatening,” ​said the Agency.

To date, AuroMedics Pharma has not received reports of any adverse events related to this recall.

The firm did not respond to a request for comment before the time of publication.

AuroMedics Pharma is the wholly owned subsidiary of Hyderabad, India-based Aurobindo Pharma.

Earlier this week​, an Economic Times story​ suggested Aurobindo Pharma was one of seven companies interested in acquiring Orchid Pharma. Aurobindo denied​ the rumours, describing the report as “factually incorrect.”

Related topics: Markets & Regulations, Regulations

Related news

Show more

Related products

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us

Products

View more

Webinars